Enzo Biochem, Inc. (NYSE:ENZ – Get Free Report) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 531,800 shares, a decrease of 10.0% from the July 15th total of 591,200 shares. Based on an average daily trading volume, of 119,600 shares, the days-to-cover ratio is presently 4.4 days. Currently, 1.5% of the company’s shares are short sold.
Enzo Biochem Stock Down 1.8 %
NYSE:ENZ traded down $0.02 during trading hours on Monday, hitting $1.11. 39,321 shares of the company were exchanged, compared to its average volume of 107,406. Enzo Biochem has a one year low of $0.99 and a one year high of $1.68. The company has a fifty day simple moving average of $1.11 and a 200 day simple moving average of $1.17.
Enzo Biochem (NYSE:ENZ – Get Free Report) last announced its earnings results on Thursday, June 13th. The medical research company reported ($0.03) EPS for the quarter. Enzo Biochem had a net margin of 134.17% and a negative return on equity of 21.50%. The company had revenue of $8.02 million during the quarter.
Institutional Investors Weigh In On Enzo Biochem
About Enzo Biochem
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Featured Articles
- Five stocks we like better than Enzo Biochem
- 3 Stocks to Consider Buying in October
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What is the Hang Seng index?
- 2 Option Strategies to Maximize Profits in a Bear Market
- 3 Healthcare Dividend Stocks to Buy
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.